TetraQ, the integrated preclinical contract research provider based at The University of Queensland, and Q-Pharm, a leading early phase clinical trial facility in Australasia, have formed a strategic alliance.
The alliance aims to enhance the delivery of bioanalytical services to clients in the biotechnology and pharmaceutical industries.
It is considered to be a positive development for the two businesses, which are both commercialisation enterprises of the University to give industry access to UQ's cutting-edge research resources and expertise.
TetraQ is a leading contract research organization that offers a broad range of preclinical services to the biopharmaceutical industry. A component of TetraQ's services includes bioanalytical services supporting clinical studies (including bioavailability/ bioequivalence and drug-drug interaction studies).
Q-Pharm is a Phase 1 clinical trial provider, servicing the early phase trial requirements of the pharmaceutical and biotech industries in Australia and around the world.
According to Q-Pharm CEO, Professor Wayne Hooper, the alignment of the two organisations at the interface of the preclinical and early phase clinical stages of the drug development pathway presented significant opportunities for capturing operational economies, co-marketing of services and cross-referral of potential clients.
"Since 2002, Q-Pharm has been one of Australia's foremost providers of bioanalytical services in support of clinical studies. When we decided to outsource our bioanalytical services to TetraQ the synergistic possibilities became more apparent," Professor Hooper said.
"We can expand our range of services to existing and future clients with TetraQ's involvement. It's a very positive step forward for both businesses as well as our clients."
TetraQ's Executive Director, Professor Maree Smith, also said there were advantages in a strategic alliance.
|Contact: Rose-Marie Pennisi|